Soy isoflavone delays the progression of thioacetamide-induced liver fibrosis in rats

References

• Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209–18.
   PubMed Web of Science ®Google Scholar
• Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008;214:199–210.
   PubMed Web of Science ®Google Scholar
• Carpino G, Morini S, Ginanni Corradini S, Franchitto A, Merli M, Siciliano M, Alpha-SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantation. Dig Liver Dis 2005;37:349–56.
   PubMedGoogle Scholar
• Moreira RK. Hepatic stellate cells and liver fibrosis. Arch Pathol Lab Med 2007;131:1728–34.
   PubMed Web of Science ®Google Scholar
• Pinzani M, Rombouts K. Liver fibrosis: from the bench to clinical targets. Dig Liver Dis 2004;36:231–42.
   PubMedGoogle Scholar
• Kurzer MS. Phytoestrogen supplement use by women. J Nutr 2003;133:1983S–1986S.
   Web of Science ®Google Scholar
• Messina M, McCaskill-Stevens W, Lampe JW. Addressing the soy and breast cancer relationship: review, commentary, and workshop proceedings. J Natl Cancer Inst 2006;98:1275–84.
   PubMed Web of Science ®Google Scholar
• Wood CE, Register TC, Franke AA, Anthony MS, Cline JM. Dietary soy isoflavones inhibit estrogen effects in the postmenopausal breast. Cancer Res 2006;66:1241–9.
   PubMedGoogle Scholar
• Sacks FM, Lichtenstein A, Van Horn L, Harris W, Kris-Etherton P, Winston M. Soy protein, isoflavones, and cardiovascular health: a summary of a statement for professionals from the american heart association nutrition committee. Arterioscler Thromb Vasc Biol 2006;26:1689–92.
   PubMed Web of Science ®Google Scholar
• Lin CY, Tsai CY, Lin SH. Effects of soy components on blood and liver lipids in rats fed high-cholesterol diets. World J Gastroenterol 2005;11:5549–52.
   PubMedGoogle Scholar
• Iqbal MJ, Yaegashi S, Ahsan R, Lightfoot DA, Banz WJ. Differentially abundant mRNAs in rat liver in response to diets containing soy protein isolate. Physiol Genomics 2002;11:219–26.
   PubMed Web of Science ®Google Scholar
• Ustundag B, Bahcecioglu IH, Sahin K, Duzgun S, Koca S, Gulcu F, Ozercan IH. Protective effect of soy isoflavones and activity levels of plasma paraoxonase and arylesterase in the experimental nonalcoholic steatohepatitis model. Dig Dis Sci 2007;52:2006–14.
   PubMed Web of Science ®Google Scholar
• Mizushige T, Mizushige K, Miyatake A, Kishida T, Ebihara K. Inhibitory effects of soy isoflavones on cardiovascular collagen accumulation in rats. J Nutr Sci Vitaminol (Tokyo) 2007;53:48–52.
   PubMedGoogle Scholar
• Strnad P, Tao GZ, Zhou Q, Harada M, Toivola DM, Brunt EM, Omary MB. Keratin mutation predisposes to mouse liver fibrosis and unmasks differential effects of the carbon tetrachloride and thioacetamide models. Gastroenterology 2008;134:1169–79.
   PubMedGoogle Scholar
• Moal F, Chappard D, Wang J, Vuillemin E, Michalak-Provost S, Rousselet MC, Oberti F, Cales P. Fractal dimension can distinguish models and pharmacologic changes in liver fibrosis in rats. Hepatology 2002;36:840–9.
   PubMed Web of Science ®Google Scholar
• Lee TH, Jawan B, Chou WY, Lu CN, Wu CL, Kuo HM, Concejero AM, Wang CH. Alpha-melanocyte-stimulating hormone gene therapy reverses carbon tetrachloride induced liver fibrosis in mice. J Gene Med 2006;8:764–72.
   PubMed Web of Science ®Google Scholar
• Pilette C, Rousselet MC, Bedossa P, Chappard D, Oberti F, Rifflet H, Histopathological evaluation of liver fibrosis: quantitative image analysis vs semi-quantitative scores. Comparison with serum markers. J Hepatol 1998;28:439–46.
   PubMedGoogle Scholar
• Vera M, Nieto N. Hepatic stellate cells and alcoholic liver disease. Rev Esp Enferm Dig 2006;98:674–84.
   PubMedGoogle Scholar
• Guyot C, Lepreux S, Combe C, Doudnikoff E, Bioulac-Sage P, Balabaud C, Desmouliere A. Hepatic fibrosis and cirrhosis: the (myo)fibroblastic cell subpopulations involved. Int J Biochem Cell Biol 2006;38:135–51.
   PubMed Web of Science ®Google Scholar
• Sato M, Suzuki S, Senoo H. Hepatic stellate cells: unique characteristics in cell biology and phenotype. Cell Struct Funct 2003;28:105–12.
   PubMed Web of Science ®Google Scholar
• Liu XJ, Yang L, Mao YQ, Wang Q, Huang MH, Wang YP, Wu HB. Effects of the tyrosine protein kinase inhibitor genistein on the proliferation, activation of cultured rat hepatic stellate cells. World J Gastroenterol 2002;8:739–45.
   PubMed Web of Science ®Google Scholar
• Gressner AM, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med 2006;10:76–99.
   PubMed Web of Science ®Google Scholar
• Hoch RV, Soriano P. Roles of PDGF in animal development. Development 2003;130:4769–84.
   PubMed Web of Science ®Google Scholar
• Abdollahi A, Li M, Ping G, Plathow C, Domhan S, Kiessling F,, Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med 2005;201:925–35.
   PubMed Web of Science ®Google Scholar
• Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999;79:1283–316.
   PubMed Web of Science ®Google Scholar
• Kershenobich Stalnikowitz D, Weissbrod AB. Liver fibrosis and inflammation. A review. Ann Hepatol 2003;2:159–63.
   PubMedGoogle Scholar
• Lee CG, Kang HR, Homer RJ, Chupp G, Elias JA. Transgenic modeling of transforming growth factor-beta(1): role of apoptosis in fibrosis and alveolar remodeling. Proc Am Thorac Soc 2006;3:418–23.
   PubMedGoogle Scholar
• Khan R, Sheppard R. Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology 2006;118:10–24.
   PubMed Web of Science ®Google Scholar
• Morris-Stiff G. TGFbeta-1 and the development of chronic graft nephropathy: relative roles of gene, mRNA and protein. Ann R Coll Surg Engl 2005;87:326–30.
   PubMedGoogle Scholar
• Murawaki Y, Ikuta Y, Idobe Y, Kitamura Y, Kawasaki H. Tissue inhibitor of metalloproteinase-1 in the liver of patients with chronic liver disease. J Hepatol 1997;26:1213–19.
   PubMed Web of Science ®Google Scholar
• Murawaki Y, Ikuta Y, Idobe Y, Kawasaki H. Serum matrix metalloproteinase-1 in patients with chronic viral hepatitis. J Gastroenterol Hepatol 1999;14:138–45.
   PubMedGoogle Scholar
• Murawaki Y, Ikuta Y, Okamoto K, Koda M, Kawasaki H. Diagnostic value of serum markers of connective tissue turnover for predicting histological staging and grading in patients with chronic hepatitis C. J Gastroenterol 2001;36:399–406.
   PubMedGoogle Scholar
• Leroy V, Monier F, Bottari S, Trocme C, Sturm N, Hilleret MN, Morel F, Zarski JP. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol 2004;99:271–9.
   PubMed Web of Science ®Google Scholar
• El-Gindy I, El Rahman AT, El-Alim MA, Zaki SS. Diagnostic potential of serum matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as non-invasive markers of hepatic fibrosis in patients with HCV related chronic liver disease. Egypt J Immunol 2003;10:27–35.
   PubMedGoogle Scholar
• Afdhal N. Can serum markers be used to reliably detect liver fibrosis? Nat Clin Pract Gastroenterol Hepatol 2005;2:132–3.
   PubMedGoogle Scholar